Front page
Nothing from your lists
What covered companies filed with the SEC, day by day.
Nothing from your lists
+ 10 more
Nothing from your lists
Clear Channel Outdoor Holdings, Inc. · “As a result of the consummation of the Merger, a change of control of the Company occurred and the Company became a wholly owned subsidiary of Parent.”¶1
Netcapital Inc. · “On October 7, 2026, the Company received a letter from Nasdaq notifying the Company that, for the 10 consecutive business days from September 23, 2026 through October 6, 2026, the closing bid price of the Company’s common stock had been at $1.00 per share or greater.”¶1
SkinHealth Systems Inc. · “On October 9, 2026, the Company issued a press release announcing that the Reverse Stock Split would become effective at 12:00 a.m. Eastern Time on October 14, 2026, a copy of which is attached as Exhibit 99.1 hereto and is incorporated herein by reference.”¶1
Nothing from your lists
Nothing from your lists
Nothing from your lists
Nothing from your lists
The Merger closed on October 14, 2026, making Clear Channel Outdoor Holdings a wholly owned subsidiary of Parent, and each share was converted into the right to receive $2.43 per share in cash.¶2¶3
The Company incurred $100 million of incremental term loans under the Credit Agreement Amendment and terminated its Revolving Credit Facility commitment, reducing it to $0.¶4¶5
The Company irrevocably deposited approximately $1,872.7 million with the trustee to pay the October 15, 2026 interest and redeem all 2028 Notes and 2029 Notes, which will be redeemed on October 24, 2026 at 100% of principal plus accrued interest.¶6
Scott Wells ceased to serve as Chief Executive Officer and President, Wade Davis was appointed President and Chief Executive Officer, and ten directors resigned from the board effective upon the Merger.
On October 12, 2026, the Board approved manufacturing network optimization initiatives, including a phased exit of operations at the Ennistymon, Ireland manufacturing facility and an exit from highly customized portions of the international transportation business.¶1¶2
The Irish Phase-Out is estimated to result in cumulative charges of approximately $13.5 million, including $11.7 million for severance, stay bonuses, and other termination benefits, and $1.0 million of asset impairments.¶3
The Company expects to incur approximately $15.8 million of non-recurring pre-tax restructuring and related charges, including approximately $7.0 million in the current fiscal quarter, with more than $18.0 million of annualized run-rate savings when fully implemented.¶4
The Company filed a correction to its Form 10-Q, stating its intended fiscal 2027 capital expenditure projection was approximately $23.4 million rather than the $13.2 million stated in the filing.¶5
On October 13, 2026, StageWise Strategies Corp. closed a Share Exchange acquiring 99.99999012% of the participatory interests in TEG SPV LLC from its Uzbek sellers for 183,098,434 shares of Common Stock.¶1¶2
The Exchange Shares represent approximately 97.3% of the Company, based on 188,142,768 shares outstanding after the exchange, and the Company was renamed TEG Overseas, Inc. upon closing.¶2¶3
On October 13, 2026, all parties to the Share Exchange Agreement agreed in writing to waive the Concurrent Financing Condition requiring at least $18,000,000 of financing at closing.¶4
Following the closing, TEG Parent owns approximately 68.30% of the Company's outstanding Common Stock and Irodakhon Abduvakhitova owns approximately 31.14%.¶5¶6
Temur Zokirov, Bahtiyor Kadirov and Elina Davidyan will resign from the Board as of the Registration Date, and Anita Mendiratta, Wesley T. Davis, Marc William Kasher, Richard Nolan Sharko and Irodakhon Abduvakhitova will join it.¶7
On October 7, 2026, Nasdaq notified Netcapital that its common stock closed at $1.00 per share or greater for 10 consecutive business days from September 23, 2026 through October 6, 2026, so Nasdaq closed the bid price matter.¶1
The Company remains out of compliance with Nasdaq Listing Rule 5250(c)(1) for failing to timely file its Form 10-K for the fiscal year ended April 30, 2026 and Form 10-Q for the quarter ended July 31, 2026, and must submit a compliance plan by October 23, 2026.¶2¶3
On October 8, 2026, the Audit Committee approved the engagement of Adeptus Partners, LLC as independent registered public accounting firm, succeeding Fruci & Associates II, PLLC, whose resignation was effective August 12, 2026.¶4¶5
Previously issued financial statements for fiscal years ended April 30, 2022 through April 30, 2025 and related unaudited interim statements should no longer be relied upon, and Adeptus will re-audit those years.¶6
Liquidia Technologies and United Therapeutics entered a settlement agreement effective October 13, 2026 resolving all ongoing litigation, with a net payment of $175.0 million to UTC and a further $145.4 million payable.¶1¶2
Liquidia agreed to file to remove the PH-ILD indication from the YUTREPIA label and to cease marketing YUTREPIA for the treatment of PH-ILD, while continuing to market it for PAH.¶3¶2
Liquidia agreed to pay Sandoz $21.75 million, Henderson $19.05 million and PBM $19.45 million to settle their interests in the RareGen Litigation, with payments due after the UTC settlement.¶4¶5¶6
Liquidia and Healthcare Royalty Partners IV agreed to a Seventh Amendment permitting a letter of credit for the settlement, increasing the minimum cash covenant from $15.0 million to $45.0 million.¶7
As of September 30, 2026, Liquidia had cash and cash equivalents of $396.1 million, and preliminary unaudited third quarter 2026 YUTREPIA net product sales were $222.7 million.¶8
Sabre Financial settled its tender offer for any and all of its outstanding 11.125% Senior Secured Notes due 2029 on October 13, 2026.¶1
The tender offer expired at 5:00 p.m., New York City time, on October 12, 2026, with $931,583,000 aggregate principal amount of 2029 SPV Notes validly tendered, representing approximately 93.16% of the outstanding notes.¶2
On October 13, 2026, Sabre Financial completed the redemption of $68,417,000.00 aggregate principal amount of remaining 2029 SPV Notes at 109.250% of principal plus accrued and unpaid interest.¶3
The Company entered into a Termination Agreement and Mutual Release on October 12, 2026 with 218 LLC and Gary Bowie, terminating the Membership Interest Purchase Agreement and the related Secured Convertible Term Note.¶1¶2
The Company executed a Promissory Note dated October 12, 2026 in the principal amount of $89,986.18 payable to Seller, maturing July 12, 2027, as settlement of obligations from the 2025 acquisition relationship.¶3¶4¶5
On October 2, 2026, the Company exchanged 10,800 shares of Series D Convertible Preferred Stock for 81 shares of Series E Preferred Stock, and then exchanged the 81 Series E shares for 1,756,507 shares of common stock.¶6¶7
On October 5, 2026, the Company agreed to exchange a $125,000 Partitioned Note with Streeterville Capital, LLC for 1,190,476 shares of common stock, issued October 6, 2026 at $0.105 per share.¶8¶9
On September 23, 2026, Streeterville and ARH Sub sent joint instructions to Lakeside Bank to release $100,000 from the DACA account to the Company.¶10
On October 7, 2026, Zone Frontier completed the sale of substantially all assets of its Cleaning Products Business to Sanzonate Holdings LLC, a Nevada limited liability company controlled by director Clayton Adams.¶1¶2
The purchase price is $3,350,000, paid at the Closing by a secured, non-convertible promissory note bearing 6% interest per annum.¶3¶2
The Company is also entitled to Earnout Payments of up to $2,250,000 and receives a 5% membership interest in the Buyer at the Closing.¶4¶5
Mr. Adams has a direct and indirect material interest in the Disposition, and the Disposition was approved by the disinterested members of the Board.¶6
SkinHealth Systems filed a certificate of amendment on October 9, 2026 to effect a 1-for-20 reverse stock split of its Class A Common Stock, effective 12:00 a.m. Eastern Time on October 14, 2026.¶2
At the special meeting held September 22, 2026, stockholders approved the Certificate of Amendment and authorized the Board to set the ratio between 1-for-5 and 1-for-20; the Board set it at 1-for-20 on September 22, 2026.¶3
The conversion rate of the 7.95% Convertible Senior Secured Notes due 2028 was adjusted proportionately to reflect the 1-for-20 Reverse Stock Split ratio.¶4
The Reverse Stock Split is expected to reduce outstanding Class A Common Stock from approximately 130.3 million to approximately 6.5 million shares.¶5
On October 8, 2026, the Company and IIP Operating Partnership, LP entered into an underwriting agreement with Stifel, Nicolaus & Company, Incorporated to issue 2,000,000 shares of 9.25% Series B Cumulative Redeemable Preferred Stock at $25.00 per share.¶2
The Underwriters were also granted a 30-day option to purchase up to an additional 300,000 shares of Series B Preferred Stock on the same terms.¶2
The Company's total net proceeds from the Offering are expected to be approximately $48.4 million, before estimated expenses and assuming no exercise of the over-allotment option.¶1
On October 13, 2026, the Company filed Articles Supplementary designating 2,300,000 shares of authorized preferred stock as 9.25% Series B Cumulative Redeemable Preferred Stock with a liquidation preference of $25.00 per share, effective upon filing.¶3
Upon issuance of the Series B Preferred Stock, the Company's ability to make distributions or redemptions on junior or parity shares will be subject to certain restrictions if distributions on the Series B Preferred Stock are not declared.¶4
On October 13, 2026, Eton entered into a license agreement with Aquestive for exclusive U.S. rights to LIBERVANT buccal film, subject to applicable regulatory approvals.¶1
Eton paid Aquestive an upfront license fee of $10.0 million and is responsible for milestone payments of up to an aggregate of $47.5 million, plus royalties at a mid-teens percentage rate on annual net sales.¶2¶3
A supply agreement with Aquestive names Aquestive the exclusive manufacturer and supplier of the Product and provides for an initial term of 20 years.¶4
Eton anticipates commercial availability of LIBERVANT in April 2027, subject to final FDA approval, and a PDUFA target action date of March 29, 2027 applies to adding ages 6 to 11.¶5
Flex completed the acquisition of EPC Power on October 14, 2026, paying $4.4 billion in cash, subject to customary adjustments, and EPC Power is now a wholly owned subsidiary.¶1
Flex funded the Consideration with borrowings under the Credit Facility and the Bridge Credit Facility, which were borrowed in amounts of $3.3 billion and $1.1 billion on October 14, 2026, plus cash on hand.¶2¶3¶4¶5
The Bridge Credit Facility matures on October 13, 2027, bears floating-rate interest, and requires a Debt/EBITDA Ratio not to exceed 4.50 to 1.00 and an Interest Coverage Ratio of not less than 3.00 to 1.00.¶3¶6
Axiom agreed to sell 200,000 shares of Series A Convertible Preferred Stock for an aggregate purchase price of $2.0 billion, with closing subject to regulatory conditions and Axiom expecting to use proceeds to repay Transaction borrowings.¶7
On October 13, 2026, SKYX Platforms Corp. completed its previously announced merger with Deako, Inc., which became a wholly-owned subsidiary of the Company.¶1¶2
At the Closing, the Company issued 25,000,000 shares of common stock as Merger Shares, subject to a 12-month lock-up, and post-Merger current shareholders will own approximately 84.4% of the Company.¶3
The Company paid the Senior Lenders an aggregate of $4,000,000 in cash on behalf of Deako and delivered a senior secured promissory note in the aggregate principal amount of $8,500,000 bearing interest at 12.0% per annum.¶4
